Psychiatry · AntipsychoticRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Risperidone by Actavis Labs

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:32:39 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Actavis Labs' supplemental application for Risperidone is a significant regulatory milestone that could strengthen their competitive position in the antipsychotic market. Portfolio teams must evaluate the potential impact on market dynamics and pricing strategies as this unfolds. Regulatory context from FDA (FDA AP — RISPERIDONE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess how this supplement could affect market dynamics and pricing strategies. The strongest clinical anchor is Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial (ClinicalTrials.gov), moderate corpus alignment. In Psychiatry · Antipsychotic, 8 regulatory and 2 competitive items passed relevance filtering for Actavis Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS. This acceptance may enhance Actavis Labs' position in the antipsychotic market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — RISPERIDONE (SUPPL) (FDA). Entity match (actavis labs). The acceptance of this supplemental application indicates a positive regulatory trajectory, but the final approval and its implications for labeling and compliance will need to be closely monitored.

Key Risks

Elevated medium regulatory exposure for Actavis Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to enhanced market share for Actavis Labs, potentially affecting pricing and competitive positioning against other antipsychotic products.
Upside for Actavis Labs may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess how this supplement could affect market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the review and any subsequent approvals or market entries.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (risperidone)
FDA document
View source
FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Entity match (risperidone)
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAhigh relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — ELTROMBOPAG OLAMINE (ORIG)
FDAhigh relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (actavis labs)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Molecular Immunohematology in Ethiopian Sub-Populations
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intrinsic Capacity, Resilience, and Meaning in Life in Community-Dwelling Midlife and Older Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Actavis Labs
Risperidone

Commercial impact

medium

The approval could lead to enhanced market share for Actavis Labs, potentially affecting pricing and competitive positioning against other antipsychotic products.

Regulatory impact

medium

The acceptance of this supplemental application indicates a positive regulatory trajectory, but the final approval and its implications for labeling and compliance will need to be closely monitored.

What to watch

Monitor the progress of the review and any subsequent approvals or market entries.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.